Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Amgen (2)
44 Articles Available
2
2
Can't find what you're looking for? Try our
advanced search
.
Celiac Disease
Amgen and Provention Bio Announce Co-Development Collaboration In Celiac Disease
PR-M11-18-NI-018
Cell and Gene Therapy
Oxford Nanopore Technologies Attracts Amgen Investment
PAO-M10-18-NI-031
Facility
Groundbreaking for Amgen in Rhode Island
PAO-M08-18-NI-017
Clinical Data
Novartis and Amgen Highlight Findings from a Large Global Patient Survey on Migranes
PR-M06-18-NI-101
Biosimilars
Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab
PR-M06-18-NI-100
Collaboration
Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Cancer
PR-M06-18-NI-028
Collaboration
Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment
PR-M05-18-NI-104
FDA Approval
Novartis and Amgen announce FDA approval of Aimovig™ (erenumab-aooe), a novel treatment developed specifically for migraine prevention
PR-M05-18-NI-081
European Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
PR-M04-18-NI-021
Approval
Amgen Gets Expanded Approval for Blincyto®
PAO-M04-18-NI-005
FDA
FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children
PR-M04-18-NI-007
Drug Delivery
Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta® (pegfilgrastim)
PR-M03-18-NI-002
Agreement
Abarca, Amgen Enter Outcomes-Based Agreement For Repatha® (evolocumab)
PR-M02-18-NI-103
Biomanufacturing
Amgen to Open Biomanufacturing Plant in the US
PAO-M02-18-NI-010
Clinical Trial
Amgen and Novartis Reach an Important Milestone
PAO-M01-18-NI-041
Oncology
Overall Survival Analysis From KYPROLIS® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology
PR-M01-18-NI-074
Drug Development
Amgen and Novartis Expand Collaboration to Prevent Alzheimer’s
PAO-M11-17-NI-009
Partnership
Amgen and CytomX Therapeutics Collaborate on the Development of Bispecific Antibodies
PAO-M10-17-NI-018
Biosimilar
FDA Approves First Biosimilar Treatment for Multiple Cancers
PAO-M09-17-NI-030
FDA Approval
Amgen’s Vectibix Approved for RAS Metastatic Colorectal Cancer
PAO-M07-17-NI-010
«
2
2
.svg)
